Characterization of a human ovarian carcinoma cell line with estrogen and progesterone receptors

Cancer

Volumn 63, Issue 2, 1989, Pages 280-288

  Geisinger, Kim R ^a   Kute, Timothy E ^b   Pettenati, Mark J ^c   Welander, Charles E ^d,e   Dennard, Yvonne ^d   Collins, Lee Ann ^d,e   Berens, Michael E ^d,f  

^a Departments of Pathology   (United States)

^b Departments of Medicine Hematology Oncology ^*  (United States)

^c Departments of Pediatrics   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

CYTOLOGY; FEMALE; HUMAN; HUMAN CELL; KARYOTYPE; OVARY CARCINOMA; PRIORITY JOURNAL; TUMOR CELL LINE; ULTRASTRUCTURE;

ADENOCARCINOMA; ANIMAL; CHROMOSOME BANDING; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FLOW CYTOMETRY; HUMAN; KARYOTYPING; MALE; MICE; MICE, NUDE; OVARIAN NEOPLASMS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SUPPORT, U.S. GOV'T, P.H.S.; TRANSLOCATION (GENETICS); TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 0024489926     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19890115)63:2<280::AID-CNCR2820630213>3.0.CO;2-N     Document Type: Article

References (84)

1. Estrogen and progestin binding in cystosols of ovarian adenocarcinoma
2. Sex steroid receptors in gynecologic cancer
3. Comparison of cytosol estrogen and progestin receptor status in malignant and benign tumors and tumor‐like lesions of human ovary
4. Ovarian carcinoma: Histologic and clinical correlation of cytoplasmic estrogen and progesterone binding
5. The occurrence of multiple steroid hormone receptors in disease‐free and neoplastic human ovary
6. Estrogen receptor and peroxidase activity in epithelial ovarian carcinomas
7. Estrogen and progesterone receptors in tumors of the human ovary
8. Cytoplasmic steroid receptors in ovarian tumours
9. Estrogen and progesterone receptors in ovarian neoplasms
10. 3H)monohydroxytamoxifen in ovarian carcinoma
11. Estrogen receptor titers in primary epithelial ovarian carcinomas
12. Clinical significance of estrogen and progestin receptors in ovarian cancer
13. 3H‐R5020 binding in cytosols of normal and neoplastic human ovarian tissue
14. Estrogen‐ and gestagen‐receptors in ovarian carcinoma
15. Ostrogen‐ und progesteronezeptoren in malignen ovarialtumoren
16. Estrogen and progesterone receptors in human ovarian tumors
17. Cytosol and nuclear estrogen and progestin receptors and 17β‐hydroxy‐steroid dehydrogenase activity in non‐diseased tissue and in benign and malignant tumors of the human ovary
18. Estradiol and progesterone receptors in normal ovary and ovarian tumors
19. Hormonal aspects of ovarian malignancy
20. 125I)‐methoxyiodovinyl estradiol in ovarian carcinomas
21. Immunocytochemical identification of estorgen receptor in ovarian carcinomas: Localization with monoclonal estrophilin antibodies compared with biochemical assays
22. Persistence and distribution of estrogen receptor in advanced epithelial ovarian carcinoma after chemotherapy
23. Histopathologic correlations of estrogen and progestin receptor protein in epithelial ovarian carcinomas
24. Steroid receptor content in human ovarian tumors: Survival of patients with ovarian carcinoma related to steroid receptor content
25. Enzyme‐linked immunochemical measurement of estrogen receptors in gynecologic tumors and an overview of steroid receptors in ovarian carcinoma
26. Merino MJ, LiVolsi VA, Kohorn EI, Eisenfeld A. Are cytosol estrogen and progestin receptors of prognostic significance in the management of epithelial ovarian cancers?
27. Progesterone in the treatment of advanced malignant tumours of breast, ovary and uterus
28. Progestogen therapy for ovarian carcinoma
29. Management of ovarian carcinoma: Current concepts and future prospects
30. Medroxyprogesterone acetate for the treatment of metastatic and recurrent ovarian carcinoma
31. The treatment of advanced cystadenocarcinoma of the ovary with gestronal and continuous oral cyclophosphamide
32. High‐dose medroxyprogesterone acetate (MPA) in advanced chemotherapy‐resistant ovarian carcinoma: A phase II study
33. A study of estrogen and progesterone cytosol receptor concentration in benign and malignant ovarian tumors and a review of malignant ovarian tumors treated with medroxy‐progesterone acetate
34. High‐dose medroxyprogesterone acetate (MPA) in advanced epithelial ovarian cancer resistant to first‐ or second‐line chemotherapy
35. Advanced ovarian carcinoma: Response to antiestrogen therapy
36. Progestin therapy for advanced ovarian cancer: A phase II Eastern Cooperative Oncology Group Trial
37. Tamoxifen therapy for advanced ovarian cancer
38. Progestogen therapy for ovarian carcinoma
39. High‐dose medroxyprogesterone acetate for the treatment of advanced ovarian carcinoma
40. Megestrol acetate for the palliation of advanced ovarian carcinoma
41. Estrogen and progestogen therapy in advanced ovarian cancer: Preliminary report
42. Tamoxifen therapy of epithelial ovarian cancer
43. Tamoxifen in a loading dose schedule in refractory ovarian cancer (Abstr)
44. 2 and cytotoxic assay
45. Rheumatoid pleural effusion: A transmission and scanning electron microscopic evaluation
46. Use of monoclonal antiestrogen receptor antibody to evaluate estrogen receptor content in fine needle aspiration in breast biopsies
47. Analysis of the relationships of the ploidy and cell cycle kinetics to differentiation and the female sex steroid hormone receptors in adenocarcinoma of the endometrium
48. Direct and indirect effects of human recombinant γ‐interferon on tumor cells in a clonogenic assay
49. Common epithelial ovarian tumors: Immunohistochemical intermediate filament profiles
50. The effect of sex steroids on the in vitro synthesis of DNA by malignant ovarian tumours
51. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR‐3) with androgen and estrogen receptors
52. Cell lines derived from human ovarian carcinomas: Growth stimulation by gonadotrophic and steroid hormones
53. Steroid receptors and response of ovarian cancer to hormones in vitro
54. Steroid receptors and response of ovarian cancer to cytostatic drugs in vitro
55. Antiproliferative actions of tamoxifen to human ovarian carcinomas in vitro
56. In vitro responsiveness of ovarian epithelial carcinomas to endocrine therapy
57. The cellular biology of a newly established cell line of human ovarian adenocarcinoma in vitro
58. Two new tissue culture lines from ovarian cancer
59. One hundred and twenty‐seven cultured human tumor cell lines producing tumors in nude mice
60. Characterization of an ovarian carcinoma cell line
61. Kinetics of growth and ectopic production of human chorionic gonadotropin by an ovarian cystadenocarcinoma cell line maintained in vitro
62. Characterization of two new human ovarian carcinoma cell lines
63. Expression of cell‐mediated immunity and blocking factor using a new line of ovarian cancer cells in vitro
64. Comparison of four new cell lines from patients with adenocarcinoma of the ovary
65. Flow cytometric and morphological studies of ovarian carcinoma cell lines and xenografts
66. Effects of Calmodulin antagonists on human ovarian cancer cell proliferation in vitro
67. Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice
68. Comparative properties of five human ovarian adenocarcinoma cell lines
69. A new human ovarian carcinoma cell line: Establishment and analysis of tumor‐associated markers
70. Radiation survival parameters of anti‐neoplastic drug‐sensitive and resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine
71. Characterization of immunotoxins active against ovarian cancer cell lines
72. A cell line from a human ovarian carcinoma with amplification of the K‐ras gene
73. Establishment of a cisplatin‐resistant human ovarian cell line
74. Establishment and characterization of three new human ovarian carcinoma cell lines and initial evaluation of their potential in experimental chemotherapy studies
75. Cytogenetic analysis of four human ovarian carcinoma cell lines
76. Cellular heterogeneity and drug resistance in two ovarian adenocarcinoma cell lines derived from a single patient
77. Induction of progesterone receptor with 17β‐estradiol in human ovarian cancer
78. Cytogenetic studies in ovarian cancer
79. Chromosome 1 in 26 carcinomas of the cervix uteri: Structural and numerical changes
80. Abnormal chromosomes including small metacentrics in 14 ovarian cancers
81. Flow cytometric analysis of DNA and cell proliferation in ovarian tumors
82. Prognostic significance of DNA index, multiploidy, and S‐phase fraction in ovarian cancer
83. Cellular DNA content and CA‐125 antigen expression in ovarian carcinomas